p53 Mutations, ras Mutations, and p53-Heat Shock 70 Protein Complexes in Human Lung Carcinoma Cell Lines

Cancer Research

Volumn 51, Issue 15, 1991, Pages 4090-4096

  Lehman, Teresa A ^a   Bennett, William P ^a   Metcalf, Robert A ^a   Welsh, Judith A ^a   Ecker, Jill ^a   Modali, Rama V ^a   Ullrich, Stephen ^a   Romano, Joseph W ^a   Appella, Ettore ^a   Testa, Joseph R ^b   Gerwin, Brenda I ^a   Harris, Curtis C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; PROTEIN P53;

ARTICLE; CARCINOGENESIS; CELL LINE; DNA SEQUENCE; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; HEAT STROKE; HUMAN; HUMAN CELL; IMMUNOCHEMISTRY; IMMUNOPRECIPITATION; LUNG CARCINOMA; ONCOGENE RAS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTO ONCOGENE; TUMOR SUPPRESSOR GENE;

BASE SEQUENCE; BRONCHI; CELL TRANSFORMATION, NEOPLASTIC; EPITHELIAL CELLS; EXONS; GENES, P53; GENES, RAS; HEAT-SHOCK PROTEINS; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MOLECULAR SEQUENCE DATA; MUTATION; PRECIPITIN TESTS; PROTEIN BINDING; PROTEIN P53; TUMOR CELLS, CULTURED;

EID: 0026397676     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (72)

1. Eliyahu, D., Michalovitz, D., Eliyahu, S., Pinhasi-Kimhi, O., and Oren, M. Wild-type p53 can inhibit oncogene-mediated focus formation. Proc. Nati. Acad. Sci. USA, 86: 8763-8767, 1989.
2. Finlay, C. A., Hinds, P. W., and Levine, A. J. The p53 proto-oncogene can act as a suppressor of transformation. Cell, 57: 1083-1093, 1989.
3. Michalovitz, D., Halevy, O., and Oren, M. Conditional inhibition of trans formation and of cell proliferation by a temperature-sensitive mutant of p53. Cell, 62:671-680. 1990.
4. Mercer, W. E., Amin, M., Sauve, G. J., Appella, E., Ullrich, S. J., and Romano, J. W. Wild type human p53 is antiproliferative in SV40-transformed hamster cells. Oncogene, 5: 973-980, 1990.
5. Mercer, W. E., Shields, M. T., Amin, M., Sauve, G. J., Appella, E., Romano, J. W., and Ullrich, S. J. Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. Proc. Nati. Acad. Sci. USA, 87:6166-6170. 1990.
6. Baker, S. J., Markowitz. S., Fearon, E. R., Willson, J. K., and Vogelstein, B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science (Washington DC), 249: 912-915, 1990.
7. Hinds, P., Finlay, C., and Levine, A. J. Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation. J. Virol., 63-739-746, 1989.
8. Nigro, J. M., Baker, S. J., Preisinger, A. C., Jessup, J. M., Hosteller, R., Cleary, K., Bigner, S. H., Davidson, N., Baylin, S., Devilee, P., Glover, T., Collins, F. S., Weston, A., Modali, R., Harris, C. C., and Vogelstein, B. Mutations in the p53 gene occur in diverse human tumor types. Nature (Loud.), 542:705-708. 1989.
9. Baker, S. J., Fearon, E. R., Nigro, J. M., Hamilton, S. R., Preisinger, A. C., Jessup, J. M., van Tuinen, P., Ledbetter, D. H., Barker, D. F., and Nakamura, Y. Chromosome 17 deletions and p53 gene mutations in colorectal carcino mas. Science (Washington DC), 244: 217-221, 1989.
10. Rodrigues, N. R., Rowan, A., Smith. M. E. F., Kerr, I. B., Bodmer, W. F., Gannon, J. V., and Lane, D. P. p53 mutations in colorectal cancer. Proc. Nati. Acad. Sci. USA, 87: 7555-7559, 1990.
11. van den Berg, F. M., Tigges, A. J., Schipper, M. E., den Hartog-Jager, F. C., Kroes, W. G., and Walboomers, J. M. Expression of the nuclear oncogene p53 in colon tumours. J. Pathol., 157: 193-199, 1989.
12. Chiba, I., Takahashi. T., Nau, M. M., D'Amico. D., Curici, D. T., Mitsudomi, T., Buchhagen. D. L., Carbone. D., Piantadosi. S., Koga, H., Reissman, P. T., Slamon, D. J., Holmes, E. C., and Minna, J. D. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Oncogene, 5: 1603-1610. 1990.
13. Iggo, R., Gatter, K., Bartek, J., Lane, D., and Harris, A. L. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet, 555:675-679, 1990.
14. Takahashi, T., D'Amico, D., Chiba, L., Buchhagen, D. L., and Minna, J. D. Identification of intronic point mutations as an alternative mechanism for p53 inactivation in lung cancer. J. Clin. Invest., 86: 363-369, 1990.
15. Takahashi, T., Nau, M. M., Chiba, I., Birrer, M. J., Rosenberg, R. K., Vinocour, M., Levitt, M., Pass. H., Gazdar, A. F., and Minna, J. D. p53: a frequent target for genetic abnormalities in lung cancer. Science (Washington DC), 246:491-494, 1989.
16. Bartek, J., Iggo, R., Gannon, J., and Lane, D. P. Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene, 5: 893-899, 1990.
17. Presser, J., Thompson, A. M., Cranston, G., and Evans, H. J. Evidence that p53 behaves as a tumour suppressor gene in sporadic breast tumors. Onco gene, 5: 1573-1579, 1990.
18. Cattoretti, G., Rilke, F., Andreola, S., D'Amato, L., and Delia, D. p53 expression in breast cancer. Int. J. Cancer, 41: 178-183. 1988.
19. Hollstein, M., Metcalf, R. A., Welsh, J., Montesano. R., and Harris, C. C. Frequent mutation of the p53 gene in human esophageal cancer. Proc. Nati. Acad. Sci. USA, 47:9958-9961, 1990.
20. Hsu, I. C., Metcalf, R. A., Sun, T., Welsh, J., Wang, N. J., and Harris, C. C. p53 gene mutational hotspot in human hepatocellular carcinomas from Qidong, China. Nature (LOND.), 550:427-428, 1991.
21. Cheng, J., and Haas, M. Frequent mutations in the p53 tumor suppressor gene in human leukemia T-cell lines. Mol. Cell. Biol., 10: 5502-5509, 1990.
22. Menon, A. G., Anderson, K. M., Riceardi, V. M., Chung, R. Y., Whaley, J. M., Yandell, D. W., Farmer, G. E., Freiman, R. N., Lee, J. K., Li, F. P., Barker, D. F., Ledbetter, D. H., Kleider, A., Martuza, R. L., Gusella, J. F., and Seizinger, B. R. Chromosome 17p deletions and pS3 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis. Proc. Nati. Acad. Sci. USA, 47:5435-5439, 1990.
23. Mulligan, L. M., Matlashewski, G., Scrable, H. J., and Cavenee, W. K. Mechanisms of p53 loss in human sarcomas. Proc. Nati. Acad. Sci. USA, 87:5863-5867, 1990.
24. Romano, J. W., Ehrhart, J. C., Duthu, A., Kim, C. M., Appella, E., and May, P. Identification and characterization of a pS3 gene mutation in a human osteosarcoma cell line. Oncogene, 4: 1483-1488, 1990.
25. Vogelstein, B. Cancer. A deadly inheritance. Nature (LOND.), 348: 681-682, 1990.
26. Eliyahu, D., Goldfinger, N., I'mhasi Rimili. O., Shaulsky, G., Skurnik, Y., Arai, N., Rotter, V., and Oren, M. Meth A fibrosarcoma cells express two transforming mutant pS3 species. Oncogene, 3: 313-321, 1988.
27. Lane, D. P., and Crawford, L. V. T antigen is bound to a host protein in SV40-transformed cells. Nature (LOND.), 278: 261-263, 1979.
28. Linzer, D. I., and Levine, A. J. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell, 17:43-52, 1979.
29. Sarnow, P., Ho, Y. S., Williams, J., and Levine, A. J. Adenovirus Elb-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells. Cell, 28: 387-394,1982.
30. Braithwaite, A. W., and Jenkins, J. R. Ability ofp53 and the adenovirus Elb 58-kilodalton protein to form a complex is determined by p53. J. Virol., 63: 1792-1799, 1989.
31. Werness, B. A., Levine, A. J., and Howley, P. M. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science (Washington DC), 248: 76-79, 1990.
32. Jenkins, J. R., Rudge, K., Chumakov, P., and Currie, G. A. The cellular oncogene p53 can be activated by mutagenesis. Nature (LOND.), 317: 816-818, 1985.
33. Oren, M., Maltzman, W., and Levine, A. J. Post-translational regulation of the 54K cellular tumor antigen in normal and transformed cells. Mol. Cell. Biol., 1: 101-110, 1981.
34. Reich, N. C., Oren, M., and Levine, A. J. Two distinct mechanisms regulate the levels of a cellular tumor antigen, p53. Mol. Cell. Biol., 3: 2143-2150, 1983.
35. Rogel, A., Popliker, M., Webb, C. G., and Oren, M. p53 cellular tumor antigen: analysis of mRNA levels in normal adult tissues, embryos, and tumors. Mol. Cell. Biol., 5: 2851-2855, 1985.
36. Burger, C., and Fanning, E. Specific DNA binding activity of T antigen subclasses varies among different SV40-transformed cell lines. Virology, 726: 19-31, 1983.
37. Pelham, H. R. Heat shock and the sorting of luminal ER proteins. EMBO J., 8.-3171-3176, 1989.
38. Finlay, C. A., Hinds, P. W., Tan, T. H., Eliyahu, D., Oren, M., and Levine, A. J. Activating mutations for transformation by p.53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol. Cell. Biol., 8:531-539, 1988.
39. Ehrhart, J. C., Duthu, A., Ullrich, S., Appella, E., and May, P. Specific interaction between a subset of the p53 protein family and heat shock proteins hsp72/hsc73 in a human osteosarcoma cell line. Oncogene, 3: 595-603, 1988.
40. Sturzbecher, H. W., Addison, C., and Jenkins, J. R. Characterization of mutant p53-hsp72/73 protein-protein complexes by transient expression in monkey COS cells. Mol. Cell. Biol., 8: 3740-3747, 1988.
41. Hinds, P. W., Finlay, C. A., Frey, A. B., and Levine, A. J. Immunological evidence for the association of p53 with a heat shock protein, hsc70. in p53-plus-ros-transformed cell lines. Mol. Cell. Biol., 7: 2863-2869, 1987.
42. Sturzbecher, H. W., Chumakov, P., Welch, W. J., and Jenkins, J. R. Mutant p53 proteins bind hsp 72/73 cellular heat shock-related proteins in SV40-transformed monkey cells. Oncogene, 7: 201-211, 1987.
43. Jenkins, J. R., Chumakov, P., Addison, C., Sturzbecher, H. W., and Wade-Evans, A. Two distinct regions of the murine p53 primary amino acid sequence are implicated in stable complex formation with simian virus 40 T antigen. J. Virol., 62: 3903-3906, 1988.
44. Gannon, J. V., and Lane, D. P. Protein synthesis required to anchor a mutant p53 protein which is temperature-sensitive for nuclear transport. Nature (LOND.), 349: 802-806, 1991.
45. Rodenhuis, S., Slebos, R. J., Boot, A. J., Evers, S. G., Mooi, W. J., Wagenaar, S. S., Van Bodegom, P. C., and Bos, J. L. Incidence and possible clinical significance of K-nu oncogene activation in adenocarcinoma of the human lung. Cancer Res., 48: 5738-5741, 1988.
46. Almoguera, C., Forrester, K., Winter, E., Lama, C., and Perucho, M. Acti vated ras genes in pulmonary carcinoma. Lung Cancer, 4: 168-170, 1988.
47. Kobayashi, T., Tsuda, H., Noguchi, M., Hirohashi, S., Shimosato, Y., Goya, T., and Hayata, Y. Association of point mutation in c-Ki-rai oncogene in lung adenocarcinoma with particular reference to cytologie subtypes. Cancer (Phila.), 66: 289-294, 1990.
48. Parada, L. F., Land, H., Weinberg, R. A., Wolf, D., and Rotter, V. Cooper ation between gene encoding p53 tumour antigen and ras in cellular trans formation. Nature (LOND.), 312: 649-651, 1984.
49. Eliyahu, D., Raz, A., Gruss, P., Givol, D., and Oren, M. Participation of p53 cellular tumour antigen in transformation of normal embryonic cells. Nature (LOND.), 312: 646-649, 1984.
50. Lacrimili, U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (LOND.), 227: 680-685, 1970.
51. Mullas, K. B., and Falcona, F. A. Specific synthesis of DNA in vitro via a polymerase-catalyzed chain reaction. Methods Enzymol., 155: 335-350, 1987.
52. Sanger, F., Nicklen, S., and Coulson, A. R. DNA sequencing with chainterminating inhibitors. Proc. Nati. Acad. Sci. USA, 74: 5463-5467, 1977.
53. Matlashewski, G. J., Tuck, S., Pirn, D., Lamb, P., Schneider, J., and Craw ford, L. V. Primary structure polymorphism at amino acid residue 72 of human p53. Mol. Cell. Biol., 7: 961-963, 1987.
54. Hidaka, Y., Palella, T. D., O'Toole, T. E., Tarie, S. A., and Kelley, W. N. Human adenine phosphoribosyltransferase. Identification of alleile muta tions at the nucleotide level as a cause of complete deficiency of the enzyme. J. Clin. Invest., 80:1409-1415, 1987.
55. Curici, D., Brantly, M., Curici, E., Stier, L., and Crystal, R. G. o,-Antitrypsin deficiency caused by the a.-antitrypsin Nullmattawa gene. An insertion mutation rendering the ai-antitrypsin gene incapable of producing 8i-antitrypsin [published erratum appears in J. Clin. Invest., 84: following p. 104, 1989]. J. Clin. Invest., 83:1144-1152, 1989.
56. Winter, E., Yamamoto, F., Almoguera, C., and Perucho, M. A method to detect and characterize point mutations in transcribed genes: amplification and overexpression of the mutant c-Ki-roc alaelein human tumor cells. Proc. Nati. Acad. Sci. USA, 82: 7575-7579, 1985.
57. Yuasa, Y., Gol, R. A., Chang, A., Chia,I. M., Reddy, E. P., Tronick, S. R. and Aaronson, S. A. Mechanism of activation of an N-ras oncogene of SW-1271 human lung carcinoma cells. Proc. Nati. Acad. Sci. USA, 81: 3670-3674, 1984.
58. Valenzuela, D. M., and Groffen, J. Four human carcinoma cell lines with novel mutations in position 12 of c-K-rai oncogene. Nucleic Acids Res., 14: 843-852, 1986.
59. Santos, E., Martin-Zanca, D., Reddy, E. P., Pierotti, M. A., Della Porta, G., and Barbacid, M. Malignant activation of a K-ros oncogene in lung carcinoma but not in normal tissue of the same patient. Science (Washington DC), 223: 661-664, 1984.
60. Mercer, W. E., and Baserga. R. Expression of the p53 protein during the cell cycle of human peripheral blood lymphocytes. Exp. Cell Res., 760: 31-46, 1985.
61. Lubbert, M., Miller, C. W., Kahan, J., and KoefTler, H. P. Expression, methylation and chromatin structure of the p53 gene in untransformed and human T-cell leukemia virus type I-transformed human T-lymphocytes. Oncogene, 4: 643-651, 1989.
62. Beckmann, R. P., Mizzen, L. A., and Welch, W. J. Interaction of Hsp 70 with newly synthesized proteins: implications for protein folding and assem bly. Science (Washington DC), 248: 850-854, 1990.
63. Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., and Howley, P. M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell, 63: 1129-1136, 1990.
64. Ciechanover, A., DiGiuseppe, J. A., Bercovich, B., Orian, A., Richter, J. D., Schwartz, A. L., and Brodeur, G. M. Degradation of nuclear oncoproteins by the ubiquitin system in vitro. Proc. Nati. Acad. Sci. USA, 88: 139-143, 1991.
65. Reddel, R. R., Ke, Y., Kaighn, M. E., Malan-Shibley, L., Lechner, J. F., Rhim, J. S., and Harris, C. C. Human bronchial epithelial cells neoplastically transformed by v-Ki-ros: altered response to inducers of terminal squamous differentiation. Oncogene Res., 3:401-408, 1988.
66. Amstad, P., Reddel, R. R., Pfeifer, A., Malan-Shibley, L., Mark, G. E., and Harris, C. C. Neoplastic transformation of a human bronchial epithelial cell line by a recombinant retrovirus encoding viral Harvey ras. Mol. Carcinog., 7: 151-160, 1988.
67. Reddel, R. R., Ke, Y., Gerwin, B. I., McMenamin, M. G., Lechner, J. F., Su, R. T., Brash, D. E., Park, J. B., Rhim, J. S., and Harris, C. C Transformation of human bronchial epithelial cells by infection with SV40 or adenovirus-12 SV40 hybrid virus, or transfection via strontium phosphate coprecipitation with a plasmid containing SV40 early region genes. Cancer Res., 48: 1904-1909, 1988.
68. Yoakum, G. H., Lechner, J. F., Gabrielson, E. W., Korba, B. E., Malan-Shibley, L., Willey, J. C., Valerio, M. G., Shamsuddin, A. K. M., Trump, B. F., and Harris, C. C. Transformation of human bronchial epithelial cells transfected by Harvey raaoncogen. Science (Washington DC), 227: 1174-1179, 1985.
69. Ura, H., Bonfil, R. D., Reich, R., Reddel, R. R., Pfeifer, A., Harris, C. C., and Klein-Szanto, A. J. P. Expression of type IV collagenase and procollagen genes and its correlation with the tumorigenic, invasive, and metastatic abilities of oncogone-transformed human bronchial epithelial cells. Cancer Res., 49:4615-4621, 1989.
70. Bonfil, R. D., Reddel, R. R., Ura, H., Reich, R., Fridman, R., Harris, C. C., and Klein-Szanto, A. J. P. Invasive and metastatic potential of a v-Ha-rastransformed human bronchial epithelial cell line. J. Nati. Cancer Inst., 87: 587-594, 1989.
71. Mabry, M., Nakagawa, T., Baylin, S., Pettengill, O. S., Sorenson, G. D., and Nelkin, B. D. Insertion of the v-Ha-ros oncogene induces differentiation of calcitonin-producing human small cell lung cancer. J. Clin. Invest., 84: 194-199, 1989.
72. Mabry, M., Nakagawa, T., Nelkin, B. D., McDowell, E., Gesell, M., Eggles ton, J. C., Casero, R. A., Jr., and Baylin, S. B. v-Ha-ros oncogene insertion: a model for tumor progression of human small cell lung cancer. Proc. Nati. Acad. Sci. USA, 85: 6523-6527, 1988.